Rechallenge with gefitinib following severe drug‑induced hepatotoxicity in a patient with advanced non‑small cell lung cancer: A case report and literature review

Chen,Xueqin; Pan,Yuelong; Zhang,Shirong; Chen,Dadong; Yang,Shaoyu; Li,Xin; Ma,Shenglin

doi:10.3892/ol.2013.1756

2014-March Volume 7 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

2014-March Volume 7 Issue 3

Full Size Image

Case Report

Rechallenge with gefitinib following severe drug‑induced hepatotoxicity in a patient with advanced non‑small cell lung cancer: A case report and literature review

Authors:
- Xueqin Chen
- Yuelong Pan
- Shirong Zhang
- Dadong Chen
- Shaoyu Yang
- Xin Li
- Shenglin Ma
View Affiliations / Copyright

Affiliations: Department of Medical Oncology, Nanjing Medical University, Affiliated Hangzhou Hospital (Hangzhou First People's Hospital), Hangzhou, Zhejiang 310006, P.R. China
Pages: 878-880
|
Published online on: December 11, 2013

https://doi.org/10.3892/ol.2013.1756
Expand metrics +

Abstract

Gefitinib has come to be the most widely used epidermal growth factor receptor‑tyrosine kinase inhibitor in the treatment of advanced non‑small cell lung cancer (NSCLC) in Asian patients. Common side effects include mild to moderate skin rash and diarrhea, however, drug‑induced liver injury of varying severity is overlooked in long‑term gefitinib administration and rarely reported. The current case report presents a female Chinese NSCLC patient who developed severe gefitinib‑induced hepatotoxicity and was rechallenged with gefitinib following a 3‑month break. The patient achieved partial clinical remission but developed drug‑induced grade 4 hepatotoxicity following gefitinib administration for 14 months. As an alternative, 4 cycles of chemotherapy were administered to control tumor progression. Following restoration of the patient's liver function, gefitinib was rechallenged together with active hepatoprotective therapy. The patient presented good disease control and maintained normal liver function for >6 months. Thus, sequential chemotherapy and gefitinib rechallenge with hepatoprotective therapy may be a potential new treatment strategy for gefitinib‑induced hepatotoxicity.

View Figures

View References

1	Ettinger DS, Akerley W, Borghaei H, et al: Non-small cell lung cancer. J Natl Compr Canc Netw. 10:1236–1271. 2012.PubMed/NCBI
2	Mok TS, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
3	Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
4	Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
5	Chen J, Gu R, Wang Q, et al: Gefitinib-induced hepatotoxicity in patients treated for non-small cell lung cancer. Onkologie. 35:509–513. 2012. View Article : Google Scholar : PubMed/NCBI
6	Ku GY, Chopra A and de Lopes GL Jr: Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity. Lung Cancer. 70:223–225. 2010. View Article : Google Scholar : PubMed/NCBI
7	Han JY, Park K, Kim SW, et al: First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 30:1122–1128. 2012. View Article : Google Scholar
8	Von Pawel J: Gefitinib (Iressa, ZDl839): a novel targeted approach for the treatment of solid tumors. Bull Cancer. 91:E70–E76. 2004.PubMed/NCBI
9	Zhou C, Wu YL, Chen G, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar
10	Zhang L, Ma S, Song X, et al: Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol. 13:466–475. 2012. View Article : Google Scholar
11	Takeda K, Hida T, Sato T, et al: Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol. 28:753–760. 2010.
12	Seki N, Uematsu K, Shibakuki R and Eguchi K: Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration. J Clin Oncol. 24:3213–3214. 2006. View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Rechallenge with gefitinib following severe drug‑induced hepatotoxicity in a patient with advanced non‑small cell lung cancer: A case report and literature review

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles